[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1985

Streptozotocin Therapy for Malignant Pheochromocytoma-Reply

Author Affiliations

Duke University Medical Center PO Box 2963 Durham, NC 27710

Arch Intern Med. 1985;145(2):368. doi:10.1001/archinte.1985.00360020212042
Abstract

—The interesting report of Gross et al certainly reinforces the fact that not all tumors of a given type will respond to an antineoplastic drug. I noted in the comments of my report that "It is also possible that it is not the difference in dose schedule but that some, but not all, patients with malignant pheochromocytomas have tumors that are sensitive to the drug (streptozotocin)."1

At the present time I cannot completely concur with Gross et al's comment "... that first line treatment, in appropriate cases, might be the recently reported radioiodinated norepinephrine analogue MIBG (meta-iodobenzylguanidine)...." In a recent report only two of five patients with malignant pheochromocytomas showed a significant clinical response to therapy with MIBG labeled with iodine 131.2 In order for a malignant pheochromocytoma to concentrate and retain MIBG 131I it is likely that the tumor will have to have an active neuronal pump

First Page Preview View Large
First page PDF preview
First page PDF preview
×